Navigation Links
Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib at 53rd American Society of Hematology Annual Meeting
Date:11/7/2011

SOUTH SAN FRANCISCO, Calif., Nov. 7, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the American Society of Hematology (ASH) Annual Meeting, December 10-13, 2011, at the San Diego Convention Center in San Diego, CA.

"The results being presented at ASH demonstrate carfilzomib's potential activity along all lines of multiple myeloma, and we are encouraged by this clinical data ranging from frontline to relapsed and refractory disease," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development and Technical Operations at Onyx Pharmaceuticals. "We are committed to bringing this promising therapy to patients as quickly as possible. We have submitted a new drug application for carfilzomib for the potential treatment of patients with relapsed and refractory multiple myeloma under the accelerated approval pathway, and also have a Phase 3 development program well underway."

Carfilzomib data highlights include:

Final Results from the Bortezomib-Naive Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma

  • Dr. Ravi Vij, Washington University School of Medicine
  • Monday, December 12, 5:00 – 5:15 p.m., Ballroom 20D
  • Oral Session: Myeloma - Therapy, excluding Transplantation: Novel drugs in relapsed/refractory myeloma patients
  • Abstract #813

Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-dose Dexamethasone in Multiple Myeloma

  • Dr. Andrzej Jakubowiak, University of Chicago
  • Monday, December 12, 2:45 – 3:00 p.m., Ballroom 20D
  • Oral Sess
    '/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Reports Third Quarter 2011 Financial Results and Highlights
2. Planet Biopharmaceuticals, Inc. Divests Assets of Allergy Control Products, Inc.
3. Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results
4. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
5. Vanda Pharmaceuticals Reports Third Quarter 2011 Results
6. Quanticel Pharmaceuticals Enters Into Strategic Cancer Drug Discovery Collaboration With Celgene Corporation
7. Cadence Pharmaceuticals Reports Third Quarter 2011 Financial Results
8. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results
10. Onyx Pharmaceuticals Reports Third Quarter 2011 Financial Results
11. Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2011 Financial Results and Provides Pipeline Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Top-Line Data Expected in the Third Quarter --, ... VIAP ), a biotechnology company focused on the development ... that,it has completed the last patient visit in its ... be analyzed to determine,VIA-2291,s effect on inflammation, and the ...
... Modigene,s CTP Technology for Extending ... of Action of Therapeutic Proteins -, NES-ZIONA, Israel, ... noted the successful completion of a Phase,III clinical trial ... uses the naturally occurring CTP,peptide to extend the duration ...
Cached Medicine Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 4VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 5Modigene Platform Validated in Independent Phase III Trial of CTP Technology 2Modigene Platform Validated in Independent Phase III Trial of CTP Technology 3
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... if parent, sibling has the movement disorder, study shows , ... of people who have restless legs syndrome are also more ... , The authors of the study, which is published in ... the findings will raise awareness of the condition for both ...
... ... syndrome , ... 2010 -- One person can make a difference, one dollar at a time: that’s the ... center for people with Trisomy 21 (better known as Down syndrome). Launched one week ago ...
... French . , Neurological research and clinical ... London and McGill University of Montreal entered an agreement ... field. Sir Keith O,Nions, Rector of Imperial, and Heather ... to sign the partnership documents, which will consolidate existing ...
... ... Sprint 4G, CradlePoint MBR1200 Router makes instant Internet access simple for small or remote ... , ... (PRWEB) May 10, 2010 -- Sprint (NYSE: S) has certified CradlePoint’s MBR1200 Failsafe Gigabit ...
... Rockville, Md., May 10, 2010 To promote ... labelsand to address the widespread problem of patient ... the U.S. Pharmacopeial Convention (USP) recently issued a ... on dispensed prescription packaging. The recommendations are patient-centered, ...
... monitored with measurement devices implanted inside a living body. ... aware of the presence of the implant. An example ... that has long since become standard treatment for heart ... of Technology (TUT) believes that the next tech-savvy generation ...
Cached Medicine News:Health News:Restless Legs Syndrome Can Have Family Ties 2Health News:Charity Asks for $1 2Health News:Trans-Atlantic agreement a boost to neuroscience research 2Health News:CradlePoint Router and Mobile Broadband Adapter Pair With Sprint 4G to Create Instant Offices, Business Continuity Solutions 2Health News:CradlePoint Router and Mobile Broadband Adapter Pair With Sprint 4G to Create Instant Offices, Business Continuity Solutions 3Health News:CradlePoint Router and Mobile Broadband Adapter Pair With Sprint 4G to Create Instant Offices, Business Continuity Solutions 4Health News:CradlePoint Router and Mobile Broadband Adapter Pair With Sprint 4G to Create Instant Offices, Business Continuity Solutions 5Health News:CradlePoint Router and Mobile Broadband Adapter Pair With Sprint 4G to Create Instant Offices, Business Continuity Solutions 6Health News:Panel recommends standardizing prescription container labeling 2Health News:Panel recommends standardizing prescription container labeling 3Health News:Panel recommends standardizing prescription container labeling 4Health News:Vital functions monitored with wearable and implantable devices 2Health News:Vital functions monitored with wearable and implantable devices 3
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
This unit is the finest standalone handswitch bipolar unit available....
...
...
Medicine Products: